Molecular mechanism of acrylamide neurotoxicity: Lessons learned from organic chemistry

Environmental Health Perspectives

Volumn 120, Issue 12, 2012, Pages 1650-1657

  LoPachin, Richard M ^a   Gavin, Terrence ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b IONA COLLEGE   (United States)

Author keywords

, unsaturated carbonyl derivatives; HSAB theory; Oxidative stress; Protein adducts; Soft electrophile; Toxic axonopathy; Type 2 alkenes

Indexed keywords

4 HYDROXYNONENAL; ACRYLAMIDE; ALDEHYDE;

CELL DAMAGE; HUMAN; NEUROPATHY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION;

ACRYLAMIDE; ALGORITHMS; ANIMALS; ECOTOXICOLOGY; HUMANS; MICE; NERVE ENDINGS; NEUROTOXICITY SYNDROMES; PROTEOMICS; RATS; RISK ASSESSMENT;

ANIMALIA;

EID: 84870565035     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205432     Document Type: Review

References (143)

1. Abou-Donia MB, Abdel-Rahman AA, Kishk AM. 2000. Neurotoxicity of ethyl methacrylate in rats. J Toxicol Environ Health A 59:97-118.
2. Almeida OP, Garrido GJ, Lautenschlager NT, Hulse GK, Jamrozik K, Flicker L. 2008. Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease. Am J Geriatr Psych 16:92-98.
3. Andre E, Campi B, Materazzi, Trevisani M, Amadesi S, Massi D, et al. 2008. Cigarette smoke-induced neurogenic inflammation is medicated by α,β-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clinical Invest 118:2574-2582.
4. Andrews LS, Clary JJ. 1986. Review of the toxicity of multifunctional acrylates. J Toxicol Environ Health 19:149-164.
5. Ansari MA, Scheff SW. 2010. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropath Exp Neurol 69:155-167.
6. Barber DS, Hunt JR, Ehrich MF, Lehning EJ, LoPachin RM. 2001. Metabolism, toxicokinetics and hemoglobin adduct formation in rat following subacute and subchronic acrylamide dosing. Neurotoxicology 22:341-353.
7. Barber DS, LoPachin RM. 2004. Proteomic analysis of acrylamide-protein adduct formation in rat brain synaptosomes. Toxicol Appl Pharmacol 201/202:120-136.
8. Barber DS, Stevens S, LoPachin RM. 2007. Proteomic analyses of rat striatal synaptosomes during acrylamide intoxication at a low dose-rate. Toxicol Sci 100:156-167.
9. Bisesi MS. 1994. Esters. 3. Esters of alkenylcarboxylic acids and monoalcohols. In: Patty's Industrial Hygiene and Toxciology (Clayton GD, Clayton FE, eds). Vol 11, 4th ed. New York:John Wiley and Sons, 2999-3007.
10. Boon PE, deMul A, van der Voet H, van Donkersgoed G, Brette M, van Klaveren JD. 2005. Calculations of dietary exposure to acrylamide. Mutat Res 580:143-155.
11. Bowyer JF, Latendresse JR, Delongchamp RR, Warbritton AR, Thomas M, Divine B, et al. 2009. The mRNA expression and histological integrity in rat forebrain motor and sensory regions are minimally affected by acrylamide exposure through drinking water. Toxicol Appl Pharmacol 240:401-411.
12. Brown RC, Lockwood AH, Sonawane BR. 2005. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113:1250-1256.
13. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. 2006. Pesticides and Parkinson's disease -is there a link? Environ Health Perspect 114:156-164.
14. Butterfield DA, Bader Lange ML, Sultana R. 2010. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochimica Biophys Acta 1801:924-929.
15. Cai J, Bhatnagar A, Pierce WM. 2009. Protein modification by acrolein: formation and stability of cysteine adducts. Chem Res Toxicol 22:708-716.
16. Calakos N, Scheller RH. 1996. Synaptic vesicle biogenesis, docking and fusion: a molecular description. Physiol Rev 76:1-29.
17. Calderón-Garcidueñas L, Kavanaugh M, Block M, D'Angiulli A, Delgado-Chávez R, Torres-Jardón R, et al. 2011. Neuroinflammation, Alzheimer's disease-associated pathology, and down-regulation of the prion-related protein in air pollution exposed children and young adults. J Alzheimers Dis 28:93-107.
18. Cataldo JK, Prochaska JJ, Glantz SA. 2010. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19:465-480.
19. Cavins, JF, Friedman M. 1968. Specific modification of protein sulfhydryl groups with α,β-unsaturated compounds. J Biol Chem 243:3357-3360.
20. Chen JC, Schwartz J. 2009. Neurobehavioral effects of ambient air pollution on cognitive performance in US adults. Neurotoxicology 30:231-239.
21. Cohen SD, Pumford NR, Khairallah EA, Boekelheide K, Pohl LR, Amouzadeh HR, et al. 1997. Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol 143:1-12.
22. Coleman P, Federoff J, Kurlan R. 2004. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63:1155-1162.
23. Coles B. 1984-1985. Effects of modifying structure on electrophilic reactions with biological nucleophiles. Drug Metab Rev 15:1307-1334.
24. Conklin DJ, Barski OA, Lesgards JF, Juvan P, Rezen T, Rozman D, et al. 2010. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicol Appl Pharmacol 24:1-12.
25. Dalle-Donne I, Vistoli G, Gamberoni L, Giustarini D, Colmbo R, Facino RM, et al. 2007. Actin Cys374 as a nucleophilic target of α,β-unsaturated aldehydes. Free Radic Biol Med 42:583-598.
26. Danielsen PH, Moller PL, Jensen KA, Sharma AK, Wallin H, Bossi R, et al. 2011. Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke particulate matter in human A549 and THP-a cell lines. Chem Res Toxicol 24:168-184.
27. Deng H, He S, Zhang S. 1993. Quantitative measurments of vibration threshold in healthy adults and acrylamide workers. Int Arch Occup Environ Health 65:53-56.
28. Doorn JA, Petersen DR. 2003. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem Bio Interact 143-144:93-100.
29. Facchinetti F, Amadei F, Geppetti P, Tarantini F, Di Serio D, Dragotto A, et al. 2007. α,β-Unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophages. Am J Resp Cell Mol Biol 37:617-623.
30. Faroon O, Roney N, Taylor J. 2008. Acrolein environmental levels and potential for human exposure. Toxicol Ind Health 24:543-564.
31. Feng Y, Forgac M. 1992. Cysteine 254 of the 73-kDa A subunit is responsible for inhibition of the coated vesicle (H+)-ATPase upon modification by sulfhydryl reagents. J Biol Chem 267:5817-5822.
32. Feron VJ, Til HP, de Vrijer F. 1991. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res 259:363-385.
33. Food and Agriculture Organization of the United Nations, World Health Organization (FAO/WHO). 2005. Joint FAO/WHO Expert Committee on Food Additives, Sixty-fourth Meeting (Contaminants). 8-17 February 2005. Rome, Italy. Available: ftp://ftp.fao.org/es/esn/jecfa/jecfa64_call.pdf [accessed 12 October 2012].
34. Forero DA, Casadesus G, Perry G, Arboleda H. 2006. Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med 10:796-805.
35. Friedman M. 2003. Chemistry, biochemistry and safety of acrylamide. A review. J Agric Food Chem 51:4504-4526.
36. Friedman M, Cavins JF, Wall JS. 1965. Relative nucleophilic reactivities of amino groups and mercaptide ions in addition reactions with α,β-unsaturated compounds. J Am Chem Soc 87:3672-3682.
37. Friedman MA, Dulak LH, Stedham MA. 1995. A lifetime oncogenicity study in rats with acrylamide. Fundam Appl Toxicol 27:95-105.
38. Friedman MA, Tyl RW, Marr MC, Myers CB, Gerling FS, et al. 1999. Effects of lactational administration of acrylamide on rat dams and offspring. Reprod Toxicol 13:511-520.
39. Friedman M, Wall JS. 1966. Additive linear free-energy relationships in reaction kinetics of amino groups with α,β-unsaturated compounds. J Org Chem 31:2888-2894.
40. Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Peigan P, et al. 2011. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol 24:651-662.
41. Fujioka K, Shibamoto T. 2006. Determination of toxic carbonyl compoiunds in cigarette smoke. Environ Toxicol 21:47-54
42. Garey J, Paule MG. 2010. Effects of chronic oral acrylamide exposure on incremental repeated acquisition (learning) task performance in Fischer 344 rats. Neurotoxicol Teratol 32:220-225.
43. Garland TO, Patterson M. 1967. Six cases of acrylamide poisoning. BMJ 4:134-138.
44. Gillette JR, Mitchell JR, Brodie BB. 1974. Biochemical mechanisms of drug toxicity. Annu Rev Pharmacol 14:271-288.
45. Grandjean P, Landrigan PJ. 2006. Developmental neurotoxicity of industrial chemicals. Lancet 368:2167-2178.
46. Grimsrud PA, Xie H, Griffin TJ, Bernlohr DA. 2008. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 283:21837-21841.
47. Green MA, Egle JL. 1983. The effects of acetaldehyde and acrolein on blood pressure in guanethidin-treated rats. Toxicol Appl Pharmacol 69:29-34.
48. Gutteridge A, Thornton JM. 2005. Understanding nature's catalytic toolkit. Trends Biochem Sci 30:622-629.
49. Haber LT, Maier A, Kroner OL, Kohrman MJ. 2009. Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Reg Toxicol Pharmacol 53:134-149.
50. Hagmar L, Wirfalt E, Paulsson B, Tornqvist M. 2005. Differences in hemoglobin adduct levels of acrylamide in the general population with respect to dietary intake, smoking habits and gender. Mutat Res 580:157-165.
51. Hamann K, Durkes, A, Ouyang H, Uchida K, Pond A, Shi R. 2008. Critical role of acrolein in secondary injury following ex vivo spinal cord trauma. J Neurochem 107:712-721.
52. He F, Zhang S, Wang H. 1989. Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ Health 15:125-129.
53. Hess DT, Matsumoto AK, Kim SO, Marshal HE, Stamler JS. 2005. Protein S-nitrosylation: pruview and parameters. Nat Rev 6:150-166.
54. Hinson JA, Roberts DW. 1992. Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Ann Rev Pharmacol Toxicol 32:471-510.
55. Howland RD. 1985. Biochemical studies of acrylamide neuropathy. Neurotoxicology 6:7-16.
56. Ismahil MA, Hamid T, Haberzetti P, Gu Y, Chandrasekar B, Srivastava S, et al. 2011. Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 301:H2050-H2060.
57. Johnson KA, Gorzinski SJ, Bodner KM, Campbell RA, Wolf CH, Friedman MA, et al. 1986. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Tox Appl Pharmacol 85:154-168.
58. Jones DP. 2010. Redox sensing: orthogonal control in cell cycle and apopotosis signaling. J Int Med 268:432-448.
59. Juan D, Zhou DHD, Li J, Wang JYJ, Gao C, Chen M. 2004. A 2-year follow-up study of cigarette smoking and risk of dementia. Europ J Neurol 11:277-282.
60. Kamel F, Hoppin JA. 2004. Association of pesticide exposure with neurological dysfunction and disease. Environ Health Perspect 112:950-958.
61. Katyare SS, Shallom JM. 1988. Altered cerebral protein turnover in rats following prolonged in vivo treatment with nicotine. J Neurochem 50:1356-1363.
62. Keating DJ. 2008. Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem 104:298-305.
63. Keller, JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, et al. 1997. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69:273-284.
64. Kiss JP. 2000. Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull 52:459-466.
65. Kutting B, Schettgen T, Schwegler U, Fromme H, Uter W, Angerer J, et al. 2009. Acrylamide as environmental noxious agent: a health risk assessment for the general population based on the internal acrylamide burden. Int J Hyg Environ Health 212:470-480.
66. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. 2005. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 113:1230-1238.
67. Lehning EJ, Balaban CD, Ross JF, LoPachin RM. 2002a. Acrylamide neuropathy: II. Spatiotemporal characteristics of nerve cell damage in brainstem and spinal cord. Neurotoxicology 23:415-429.
68. Lehning EJ, Balaban CD, Ross JF, LoPachin RM. 2003. Acrylamide neuropathy: III. Spatiotemporal characteristics of nerve cell damage in forebrain. Neurotoxicology 24:125-136.
69. Lehning EJ, Balaban CD, Ross JF, Reid MA, LoPachin RM. 2002b. Acrylamide neuropathy: I. Spatiotemporal characteristics of nerve cell damage in cerebellum. Neurotoxicology 23:397-414.
70. Lehning EJ, Persaud A, Dyer KR, Jortner BS, LoPachin RM. 1998. Biochemical and morphologic characterization of axon degeneration in acrylamide peripheral neuropathy. Toxicol Appl Pharmacol 151:211-221.
71. Levesque S, Surace MJ, McDonald J, Block ML. 2011. Air pollution & the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. J Neuroinflamm 8:105-115.
72. Liebler DC. 2008. Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol 21:117-128.
73. Lin RC, Scheller RH. 2000. Mechanisms of synaptic vesicle exocytosis. Ann Rev Cell Dev Biol 16:19-49.
74. Lipton SA, Chio YB, Takahasi H, Zhang D, Weizhong L, Godzik A, et al. 2002. Cysteine regulation of protein function as exemplified by NMDA-receptor modulation. Trends Neurosci 94:240-255.
75. LoPachin RM. 2004. The changing view of acrylamide neurotoxicity. Neurotoxicology 25:617-630.
76. LoPachin RM, Balaban CD, Ross JF. 2003. Acrylamide axonopathy revisited. Toxicol Appl Pharmacol 188:135-153.
77. LoPachin RM, Barber DS. 2006. Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicol Sci 94:240-255.
78. LoPachin RM, Barber DS, Gavin T. 2008a. Molecular mechanisms of the conjugated α,β-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases. Toxicol Sci 104:235-249.
79. LoPachin RM, Barber DS, Geohagen BC, Gavin T, He D, Das S. 2007a. Structure-toxicity analysis of type-2 alkenes: in vitro neurotoxicity. Toxicol Sci 95:136-146.
80. LoPachin RM, Castiglia CM, Lehning EJ, Saubermann AJ. 1993.Effects of acrylamide on subcellular distribution of elements in rat sciatic nerve myelinated axons and Schwann cells. Brain Res 608:238-246.
81. LoPachin RM, Castiglia CM, Saubermann AJ. 1992. Effects of acrylamide on elemental composition and water content of rat tibial nerve. I. Myelinated axons. Toxicol Appl Pharmacol 115:21-34.
82. LoPachin RM, DeCaprio AP. 2005. Protein adduct formation as a molecular mechanism in neurotoxicity. Tox Sci 86:214-225.
83. LoPachin RM, Gavin T, Barber DS. 2008b. Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases. Neurotoxicology 29:871-882.
84. LoPachin RM, Gavin T, DeCaprio AP, Barber S. 2012. Application of the Hard and Soft, Acids and Bases theory to toxicant-target interactions. Chem Res Toxicol 25:239-251.
85. LoPachin RM, Gavin T, Geohagen BC. 2009a. Synaptosomal toxicity and nucleophilic targets of 4-hydroxy-2-nonenal. Toxicol Sci 107:171-181.
86. LoPachin RM, Gavin T, Geohagen BC, Das S. 2007b. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft-soft interactions described by quantum mechanical parameters. Toxicol Sci 98:561-570.
87. LoPachin RM, Gavin T, Petersen DR, Barber DS. 2009b. Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. Chem Res Toxicol 22:1499-1508.
88. LoPachin RM, He D, Soma D. 2006. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles. Toxicol Sci 89:224-234.
89. LoPachin RM, Lehning EJ. 1994. Acrylamide-induced distal axon degeneration: a proposed mechanism of action. Neurotoxicology 15:247-260.
90. LoPachin RM, Lehning EJ, Opanashuk LA. 2000. Rate of neurotoxicant exposure determines morphologic manifestations of distal axonopathy. Toxicol Appl Pharmacol 167:75-86.
91. LoPachin RM, Lehning EJ, Ross JF, Reid M, Das S, Mansukhani S. 2002a. Neurological evaluation of toxic axonopathies in rats: acrylamide and 2,5-hexanedione. Neurotoxicology 23:95-110.
92. LoPachin RM, Ross JF, Lehning EJ. 2002b. Nerve terminals as the primary site of acrylamide action: a hypothesis. Neurotoxicology 23:43-59.
93. LoPachin RM, Schwarcz AI, Mansukhani S, Das S. 2004. In vivo and in vitro effects of acrylamide on synaptosomal neurotransmitter uptake and release. Neurotoxicology 25:349-363.
94. Luo J, Hill BG, Gu Y, Cai J, Srivastava S, Bhatnagar A, et al. 2007. Mechanisms of acrolein-induced myocardial dysfunction: implications of environmental and endogenous aldehyde exposure. Am J Physiol Heart Circ Physiol 293:H3673-H3684.
95. Martenson CH, Sheetz MP, Graham DG. 1995. In vitro acrylamide exposure alters growth cone morphology. Toxicol Appl Pharmacol 131:119-129.
96. Martyniuk CJ, Fang B, Koomen JM, Gavin T, Barber DS, LoPachin RM. 2011. Molecular mechanism of glyceraldehyde-3-phosphate dehydrogenase inactivation by α,β-unsaturated carbonyl derivatives. Chem Res Toxicol 24:2302-2311.
97. Miller MS, Spencer PS. 1985. The mechanisms of acrylamide axonopathy. Ann Rev Pharmacol Toxicol 25:643-666.
98. Mohr S, Stamler JS, Brune B. 1994. Mechanism of covalent modification of glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agents. FEBS Lett 348:223-227.
99. Morel P, Neely MD, Quinn JF, Beal FM, Markesbery WR, Robers LJ, et al. 2002. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem Int 33:531-540.
100. Moretto N, Facchinetti F, Southworth T, Civelli M, Signh D, Patacchini R. 2009. α,β-Unsaturated aldehydes in contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am J Physiol Lung Cell Mol Physiol 296:L839-L848.
101. Mucci LA, Dickman PW, Steinneck G, Adami HO, Augustsson K. 2003. Dietary acrylamide and cancer of the large bowel, kidney and bladder: absence of an association in a population-based study in Sweden. Br J Cancer 88:84-89.
102. Nam DT, Arseneault M, Murthy V. Ramassamy C. 2010. Potential role of acrolein in neurodegeneration and in Alzheimer's Disease. Curr Mol Pharmacol 3:66-78.
103. Nerland DE, Cai J, Benz FW. 2003. Selective covalent binding of acrylonitrile to Cys 186 in rat liver carbonic anhydrase III in vivo. Chem Res Toxicol 16:583-589.
104. O'Toole TE, Conklin DJ, Bhatnagar A. 2008. Environmental risk factors for heart disease. Rev Environ Health 23:167-202.
105. Parent RA, Caravello HE, Sharp DE. 1996. Metabolism and distribution of [2,3-14C]acrolein in Sprague-Dawley rats. J Appl Toxicol 16:449-457.
106. Pearson RG. 1990. Hard and soft acids and bases-the evolution of a chemical concept. Coord Chem Rev 100:403-425.
107. Perez HL, Segerback D, Osterman-Golkar S. 1999. Adducts of acrylonitrile with hemoglobin in nonsmokers and in participants in a smoking cessation program. Chem Res Toxicol 12:869-873.
108. Peters R, Poulter R, Warner J, et al. 2008. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatrics 8:36-42.
109. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA. 2001. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membrane: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39:141-149.
110. Rice JM. 2005. The carcinogenicity of acrylamide. Mutat Res 580:3-20.
111. Rozman KK, Klaassen CD. 2001. Absorption, distribution and excretion of toxicants. In: Toxicology: The Basic Science of Poison (Klaaseen CD, ed). New York:McGraw-Hill, 119-124.
112. Rudkouskaya A, Sim V, Shah AA, Feustel PJ, Jourd'Heuil D, Mongin AA. 2010. Long-lasting inhibition of presynaptic metabolism and neurotransmitter release by protein S-nitrosylation. Free Radic Biol Med 49:757-769.
113. Sadoh DR, Sharief MK, Howard RS. 1999. Occupational exposure to methyl methacrylate monomer induces generalized neuropathy in dental technician. Brit Dental J 186:380-381.
114. Schultz TW, Carlson RE, Cronin MTD, Hermens JLM, Johnson R, O'Brien PJ, et al. 2006. A conceptual framework for predicting the toxicity of reactive chemicals: modeling soft electrophilicity. SAR QSAR Eviron Res 17:413-428.
115. Schultz TW, Netzeva TI, Roberts DW, Cronin MTD. 2005. Structure-toxicity relationships for the effects to Tetrahymena pyriformis of aliphatic, carbonyl-containing α,β-unsaturated chemicals. Chem Res Toxicol 18:330-341.
116. Schwobel JAH, Koleva YK, Enoch SJ, Bajot F, Hewitt M, Madden JC, et al. 2011. Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem Rev 111:2562-2596.
117. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791.
118. Seppalainen AM, Rajaniemi R. 1984. Local neurotoxicity of methyl methacrylate among dental technicians. Am J Ind Med 5:471-477.
119. Sickles DW, Stone D, Friedman MA. 2002. Fast axonal transport: a site of acrylamide neurotoxicity? Neurotoxicology 23:223-251.
120. Singh M, Nam ST, Arseneault M, Ramassamy C. 2010. Role of by-products of lipid oxidation in Alzhimer's disease brain: a focus on acrolein. J Alzheimers Dis 21:741-756.
121. Smith CJ, Perfetti TA, Rumple MA, Rodgman A, Doolittle DJ. 2000. "IARC group 2A carcinogens" reported in cigarette mainstream smoke. Food Chem Toxicol 38:371-383.
122. Smith EA, Oehme FW. 1991. Acrylamide and polyacrylamide: a review of production, use, environmental fate and neurotoxicity. Rev Environ Health 9:215-228.
123. Spencer PS, Sabri MI, Schaumburg HH, Moore DL. 1979. Does a defect of energy metabolism in the nerve fiber underlie axonal degeneration in poly-neuropathies? Ann Neurol 5:501-507.
124. Spencer PS, Schaumburg HH. 1974a. A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure. Can J Neurol Sci 1:151-169.
125. Spencer PS, Schaumburg HH. 1974b. A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can J Neurol Sci 1:170-192.
126. Srivastava S, Sithu SD, Vladykovskaya E, Haberzetti P, Hoetker DJ, Siggiqui MA, et al. 2011. Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis 215:301-308.
127. Stevens JF, Maier CS. 2008. Acrolein: sources, metabolism and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res 52:7-25.
128. Struve MF, Wong VA, Marshall MW. 2008. Nasal uptake of inhaled acrolein in rats. Inhal Toxicol 20:217-225.
129. Sultana R, Butterfield DA. 2010. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19:341-353.
130. Sun J, Xin C, Eu JP, Stamler JS, Meissner G. 2001. Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc Natl Acad Sci USA 98:11158-11162.
131. Takahashi M, Shibutani M, Nakahigashi J, Sakaguchi N, Inoue K, Morikawa T, et al. 2009. Limited lactational transfer of acrylamide to rat offspring on maternal oral administration during the gestation and lactation periods. Arch Toxicol 83:785-793.
132. Thomas JA, Poland B, Honzatko R. 1995. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch Biochem Biophys 319:1-9.
133. Tilson HA. 1979. The neurotoxicity of acrylamide: an overview. Neurobehav Toxicol Teratol 3:445-461.
134. Tornqvist M. 2005. Acrylamide in food: the discovery and its implications. In: Chemistry and Safety of Acrylamide in Food (Friedman M, Mottram D, eds). New York:Springer Science and Business Media, 1-19.
135. Tucek M, Tenglerova J, Kollarova B. 2002. Effect of acrylate chemistry on human health. Int Arch Occup Environ Health 75:S67-S72.
136. Tyl RW, Marr MC, Myers CB, Ross WP, Friedman MA. 2000. Relationship between acrylamide reproductive and neurotoxicity in male rats. Reprod Toxicol 14:147-157.
137. Uchida K. 2003. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42:318-343.
138. Wang GW, Guo Y, Vondriska TM, Zhang J, Zhang S, Tsai LL, et al. 2008. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCε signaling and cardioprotection. J Mol Cellular Cardiol 44:1016-1022.
139. Werley MS, Freelin SA, Wrenn SE, Gerstenberg B, Roemer E, Schramke H, et al. 2008. Smoke chemistry, in vitro and in vivo toxicology evaluations of the electrically heated cigarette smoking system series K. Reg Toxicol Pharmacol 52:122-139.
140. Woodruff TJ, Wells EM, Holt EW, Burgin DE, Axelrad DA. 2007. Estimating risk from ambient concentrations of acrolein across the United States. Environ Health Perspect 115:410-415.
141. Winterbourn CC, Hampton MB. 2008. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 45:549-561.
142. Zarkovic K. 2003. 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24:293-303.
143. Zhang L, Gavin T, Barber D, LoPachin RM. 2011. Role of the Nrf2-ARE pathway in acrylamide neurotoxicity. Toxicol Lett 205:1-7.